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Summary The effect of melphalan alone or combined with various schedules of misonidazole (MISO) has
been tested on a murine fibrosarcoma. The tumoricidal effect has been determined using the growth delay
assay. Large single doses (500-1000mgkg-1) of MISO enhanced the anti-tumour effect of melphalan,
especially at high melphalan doses. This was accompanied by a drop in body and tumour temperature and an
increase in the melphalan half-life. The MISO-induced hypothermia was prevented in one experiment by
keeping the mice in an ambient temperature of 35°C for 3 h. This reduced the exposure to melphalan but did
not diminish the cytotoxic effect of the drug combination.
Chronic administration of MISO for an 8h period gave no enhancement of melphalan damage, whether
melphalan was given half-way through or at the end of the period of dosing. It seems that a threshold tumour
concentration of MISO, in excess of 70 pgg- , is needed for enhancement of melphalan cytotoxicity;
prolonged exposures to very low doses are ineffective.
Hypoxic cell radiosensitizers such as misonidazole
(MISO) have been shown to enhance the cytoxicity
of certain chemotherapeutic agents in a variety of
mouse tumours (see reviews by McNally, 1982;
Millar, 1982; Siemann, 1982). The majority of the
studies have been with single doses and most have
shown that chemotherapeutic enhancement occurs
after high doses of MISO which would, however,
have no clinical relevance (McNally, 1982; Millar,
1982; Siemann, 1982). These single dose studies are
difficult to translate directly into clinical terms,
because of the 10-fold difference between mouse
and man in the half-life of MISO, particularly since
the cytotoxic effect to MISO is reported to be a
supralinear function of exposure time (Hall et al.,
1978; Stratford & Adams, 1978). A few murine
studies have been reported in which the human
pharmacokinetics with lower plasma levels of
MISO have been simulated by multiple injection
schedules in order to assess the possible role of
chemosensitization by MISO in the clinic (Hirst &
Brown, 1982; McNally et al., 1983; Twentyman &
Workman, 1983). Some of these studies have
demonstrated significant chemosensitization, but it
is not a universal finding.
In this paper we report a comparison of the
response of a fibrosarcoma (SA FA) to melphalan
given in combination with large single doses of
MISO, or small but prolonged exposures. The
effect of each drug on the pharmacokinetics of the
other has been measured, together with the
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influence of these two drugs on body and tumour
temperature. In addition, the influence of MISO
induced hypothermia has been investigated by
maintaining some of the animals in a 35°C
environment shortly after drug administration to
prevent the hypothermia.
Materials and methods
Mice and tumours
The fibrosarcoma SA FA grown in WHT/Gy f
BSVS mice has been used. This tumour arose
spontaneously and was maintained by serial
passage in the inbred strain of origin at the Gray
Laboratory for many years. For the last 4 years the
cells have been kept in liquid nitrogen and no more
than ten transplants have been used before taking
fresh cells from the frozen store. All experiments
have been performed with Category 4 specific
pathogen free mice.
Drugs
All drugs were freshly prepared on the day of the
experiment. Melphalan was first dissolved in 0.5ml
of acid alcohol (2% HCI in ethanol) and then
further diluted with 9.5ml of sterile saline
immediately before administration (final pH2). It
was administered i.p. according to the body weight
of each animal in a volume of 0.01 mlg-1. In all
the single dose studies MISO was administered i.p.
immediately after the melphalan. For the chronic
exposures 0.01 mlg- of a standard MISO solution
was used, to give a priming dose of 120mgkg-1,
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followed by top up doses of 30 mgkg 1 every
20min for 8h.
Assays
Growth delay
Tumours were implanted by trochar s.c. on the
back and treated when they reached a mean
diameter of 7.5 + 1 mm. Each tumour was measured
2-3 times a week in 3 orthogonal diameters and the
geometric mean diameter was calculated for each
tumour. Dose response curves were constructed by
assessing the time taken for each tumour to grow
to 4.5 mm above the treatment size, thus obtaining
a growth delay (± s.e.) for each dose group
(usually 6-10 animals). In those dose groups where
the data have been pooled from several
experiments, the number of mice in a group ranges
from 19-54.
Temperature measurements
Rectal and tumour temperatures were taken on
unanaesthetised mice using a special copper
constantan thermocouple connected to a direct
reading thermocouple amplifier (Bailey Instruments,
USA). Mice were maintained in ambient
temperatures of 21°C or 35°C.
Pharmacology
Blood was collected under penthrane anaesthesia
from blood vessels in the neck and immediately
cooled on ice in heparinized tubes. It was
centrifuged at 4°C, the plasma removed and frozen
in a liquid nitrogen/alcohol mixture at -70°C and
stored at -20°C prior to analysis. Tumours were
excised immediately after the blood collection and
frozen in a similar manner. Blood and tumour
concentrations of MISO were determined by high
performance liquid chromatography (HPLC) using
a method similar to that described by Dische et al.
(1979). For melphalan analysis, aliquots of plasma
were deproteinised with 4 vol of acetonitrile
containing 1% HC1, mixed and centrifuged; an
aliquot of supernatant was dried on a Savant
sample concentrator. Tumours were homogenized
in 3 vol of 10mM HC1 and an aliquot was
deproteinised with acetonitrile, mixed, centrifuged
and the supernatant taken to dryness. Samples were
then suspended in eluent and injected on to the
HPLC column. The conditions used were 40%
acetonitrile, 5 mM heptane sulphonic acid, 2mM
dibutylamine, 40mM orthophosphoric acid, 10mM
sodium dihydrogen orthophosphate, pH 2.7. A flow
rate of 2mlmin- was used with a Waters Wisp
injector, hypersil ODS column, Waters 441 UV
detector operating at 254nm and a Waters 730 data
module.
Results
The response of the tumour SA FA to graded doses
of melphalan is plotted in Figure 1, as additional
time taken to grow from 7.5 to 12mm mean
diameter relative to controls. Untreated tumours
took 12-14 days to reach this size. In Panel A the
response is shown to graded doses of melphalan
given alone or shortly before MISO. This represents
pooled data from 3-8 experiments and contains 19-
54 mice per point. Increasing growth delay was
seen with increasing melphalan dose. One thousand
mgkg-1 MISO (given without melphalan) gave -2
days delay in growth. This MISO dose also
enhanced the growth delay obtained with all
melphalan doses, especially at the higher doses. A
much smaller but significant, sensitization was also
seen with 500mgkg-1 MISO although no delay
was seen with an intermediate dose (670mgkg-1)
of MISO given alone (data not shown). The growth
delays obtained by melphalan or MISO alone or
when MISO was combined with 10mgkg-1 of
melphalan are given in Table I. Panel B in Figure 1
shows growth delay data obtained using chronic
administration of MISO over an 8h period, with
graded doses of melphalan being administered
either halfway through (i.e. at 4h) or at the end of
the chronic MISO administration. This more
closely simulates what might occur in man where
low MISO doses would be given, but the longer
biological half-life in humans would maintain the
MISO levels for many hours. No significant
sensitization was seen with either of the chronic
dosage regimes, at any dose level (Table I).
A similar experiment was performed with
cyclophosphamide and the results were essentially
the same (data not shown). A significant
enhancement was seen with 1000mgkg-1 MISO at
all cyclophosphamide doses ranging from 40-
160mgkg-1. However, no enhancement was seen at
any dose level with an 8 h chronic MISO exposure,
whether the cyclophosphamide was given in the
middle or at the end of the chronic MISO schedule.
Temperature effects
Several authors have reported changes in body
temperatures after high doses of MISO and these
could contribute to the observed effects on the
tumour. We have therefore measured the tem-
peratures of both the tumour and the body core for
a period of 5-6h after drug administration. The
results are shown in Table I. At 21°C the rectal
temperatures of untreated mice were in the range ofCHEMOSENSITIZATION OF MELPHALAN BY MISO
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Figure 1 Growth delay as a function of melphalan dose (a) (0) melphalan alone (19-56 tumours/point); (0)
melphalan +1000mgkg- MISO (19-56 tumours/point). (b) (V) chronic exposure to 70pgg- 1 MISO for 8 h
with melphalan given halfway through (8-10 tumours per point); (A) chronic exposure to 70 pugg-1 MISO
for 8h with melphalan given at the end (8-10 tumours per point); (Q) melphalan alone (8 tumours per
point). Enhancement is only seen with the large MISO dose.
Table I Effects of administering MISO or melphalan alone or in combination
Tumour
Conditions Temperature drop °C MISO Melphalan response
Tumour
Peak Tumour
MISO Melphalan Ambient - 3 h 3-6h conc AUC Plasma AUC Growth delay
mgkg-1 mgkg-1 temp °C Rectal Tumour Rectal Tumour yigg-1 1igh-1 T1min ,igmin-1 (days)
Acute
1000 21 -5 -`5 -4 -4 702+27 1545+ 195 - 2.3+0.6
1000 10 21 -5 -5 --4 -4 NA NA 59+7 924+267 12.8+1.2
1000 35 I'll -1 - 3 -3 603+ 135 1714+283 0
1000 10 35 -1 -1 - 3 ---3 NA NA 48+ 13 558+ 172 17.9+7.6
500 - 21 -3 -3 --1 -0.5 223+ 19 402+78 0
500 10 21 -3 NA -1 NA NA NA 41+6 626+150 6.1+1.1
0 10 21 0 0 0 0 24+3 316+69 3.1+0.7
0 10 35 0 0 0 0 24+4 364+101 2.6+1.0
Chronic
8h 21 -1 -1 -1 -1 -70 573+60 0
8h 10(4) 21 NA NA NA NA NA NA NA NA 7.0+0.9
8h 10(8) 21 NA NA NA NA NA NA 30+6 275+67 6.5+0.7
Oa 21 0 0 0 0 0
0 10 21 NA NA NA NA 26+ 2a 344+ 89a 5.3+0.7
NA-data not available.
aWith chronic administration of saline every 20min for 8h.
a
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38.0+0.5°C, but the tumour temperatures were
always -3°C lower (35.2+0.2°C). Large single
doses of MISO caused a temperature drop which
was dose dependent and which persisted for at least
5h in animals kept at normal room temperature
(21°C). This hypothermia was apparent in both
rectal and tumour measurements. They both fell by
3°C after 500mgkg-1 and by - 5°C after
1000mgkg -. In this way the initial difference in
temperature between the tumour and the body core
was maintained (Table I). The addition of
10mgkg-1 melphalan did not alter this hypo-
thermic response.
Maintaining the mice in a warm room at 35°C
for 3h after administration of the drugs prevented
the rectal temperature falling below 35.5°C, and the
tumours were in the range 34-36°C. Even after 3 h,
however, a prompt drop in body and tumour
temperature resulted when the animals were
returned to a 21°C environment. Again the presence
of melphalan did not influence this MISO-induced
hypothermia.
There was a decrease by - 1°C in the rectal and
tumour temperatures of mice given repeated MISO
injections compared with those given an equivalent
volume of saline using the same schedule. These
temperature variations were small compared to
21 C
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those after large single doses, and did not lead to
consistent or prolonged hypothermia.
The influence of this hypothermic effect of MISO
on the chemosensitivity was investigated in one
experiment by keeping mice at different ambient
temperatures for 3h after drug administration. The
results are shown in Figure 2. Mice from the same
transplant were randomly allocated to the two
temperature regimes. In the left hand panel the
response of mice kept at room temperature is
shown. The effect of MISO in this particular
experiment is similar to that for the pooled data in
Figure IA. The area enclosed by + s.e. on each
point is reproduced (Figure 2B) for comparison
with the response of tumours maintained for 3 h at
35°C after receiving the drugs. There was no
significant differences in the effect of melphalan
alone but the response of mice treated with both
drugs at 35°C was consistently greater than those
maintained at room temperature for all melphalan
doses above 2.5mgkg-1. However, this treatment
was also more toxic; 3/8 and 5/8 mice died within 7
days after 7mgkg-1 and 10mgkg- melphalan
when it was combined with MISO and the elevated
temperature, compared with no deaths at room
temperature. A further experiment was performed
in which the melphalan dose was kept constant at
35 C
0 5 10 15 0 5 10
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Figure 2 Effect of ambient temperature on the tumour response to melphalan alone or combined with
1000mgkg-1 MISO. (a) 21°C; (b) 35°C. The enhancement by MISO persists when the mice are kept at 35°C
for 3h after drug administration. Hatched area in panel (b) is represented from panel (a).CHEMOSENSITIZATION OF MELPHALAN BY MISO
10mgkg- and the MISO dose was varied from
200 to 1000mgkg-1 (data not shown). As in Figure
2B an increased effect of the drug combination was
seen if the mice were kept at 35°C instead of at
21°C.
Pharmacokinetics
The effect of drug dose and body temperature on
the pharmacokinetics of both drugs has been
studied. Melphalan (10mgkg-1) has no effect on
the pharmacokinetics of MISO (1000mgkg-1) at
21°C or 35°C (data not shown). Figure 3 shows the
concentration of MISO (in the absence of
melphalan) in blood and tumour as a function of
time after injection. Each point represents the mean
of 3 mice + s.e. The top panels show the data after
a large single dose for mice kept at 21PC (A) and at
35°C for 8h after drug administration (B). For
a
both groups the tumour concentration stayed
consistently below that in blood for at least 6h.
The peak tumour level was reached more rapidly in
mice at 35°C than in those at room temperature,
and the clearance of the MISO from both blood
and tumour was slower. Panel C shows that lower
blood and tumour levels were achieved after
500mgkg-1 MISO, approximately in proportion to
the administered dose. During the chronic MISO
administration (panel D) a fairly constant level of
-100jugml - 1 was achieved in blood, and 70,gg-
in the tumour.
The peak concentration and the exposure dose,
calculated from the area under each curve (AUC)
for tumour MISO levels are shown in Table I.
Although an 8h exposure in the warm room was
used for the pharmacology this was subsequently
found to be too toxic for the growth delay
experiments; animals died within a week after
b
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Figure 3 Misonidazole concentrations in blood (0) and tumour (D) after the four schedules. The tumour
concentration generally stays below that in blood. Each point is the mean + s.e. for 3 animals. (a)
1000mgkg- 1 MISO acute 21°C; (b) 1000mgkg- 1 MISO acute 35°C; (c) 500mgkg- 1 MISO acute 21°C; (d)
chronic MISO 21°C.
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Figure 4 Melphalan concentrations in tumours after 10mgkg-I melphalan alone (0) or combined with
MISO (0). Large single doses of MISO prolong the melphalan half life (a-c) but chronic low doses have no
effect (d). Each point represents the mean + s.e. of 3 animals.
giving both drugs and maintaining them for 8 h at
35°C. The AUC for MISO for mice maintained at
35"C in Table I may therefore be a slight
overestimate. However, since the concentration had
fallen to 10% of peak levels by 3 h this is unlikely
to be a major source of error.
The melphalan concentration was determined for
both tumour and plasma in mice given melphalan
(l0mgkg-1) or combined with MISO. The plasma
melphalan half lives are shown in Table I. The
tumour results are shown in Figure 4 for all the
doseage regimes. The single doses of MISO
prolonged the melphalan half life, but there was no
influence on melphalan pharmacokinetics when low
levels of MISO were maintained for 8 h. The
tumour exposure to melphalan (i.e. area under the
curve) is listed in Table I.
Discussion
These data demonstrate that the chemosensitizing
effects of MISO which can be shown with large
doses are lost if, in an attempt to mimic the likely
pharmacokinetics in human tumours, the drug is
given as a low-dose chronic exposure. No enhance-
ment of melphalan (or cyclophosphamide) cyto-
toxicity was observed when it was given either
halfway through or at the end of an 8h chronic
MISO administration. This is, of course, dis-
appointing for the clinical application of MISO in
chemotherapy.
The other published studies of MISO and
melphalan combinations are summarised in Table
II, and a similar conclusion can be drawn from
them. With large single doses a significant effect isCHEMOSENSITIZATION OF MELPHALAN BY MISO 225
Table II Efficacy ofmelphalan combined with MISO: Comparison of literature reports.
Single doses
MISO dose Enhancement
Author Tumour mgkg-1 Ratio
Clement et al. (1980) M5076 600-1000 1.9-2.2
Fu et al. (1981) SQ 1 500 No effect
Martin et al. (1981) WH FIB 1000 2.7a
McNally et al. (1983) WH FIB 800 2.7a
WH FIB 800 1.4-2.0
Randhawa et al. (1982) CA NT 800 1.1-1.5
SA FA 1000 1.8-5.3
Rose et al. (1980) Lewis Lung Ca. 1000 2.0-2.7a
330 >1
Sheldon et al. (1982) MT 500 1.7a
Stephens et al. (1981) Lewis Lung Ca. 750 2.Oa
Hx32 1000 1.9a
Twentyman & RIF I 500 No effect
Workman (1982) RIF I 500 No effecta
KHT 500 No effect
EMT 6 500 No effect
Clutterbuck et al. (1982) HX 34 1000 > 1.0
HX 47 1000 >1.0
Present Study SA FA 1000 2.0+0.2b
SA FA 1000 (35°C) 4.3+ 1.Ob
SA FA 500 1.4+0.2b
Chronic
Administration
MISOconc. MISOconc. Exposure
in blood in tumour time Enhancement
Author Tumour ,ugml-1 ,gg- (h) ratio
Hirst (1982) RIF 1 100-200 7 2.0
McNally et al. (1983) WH FIB 100 8 No effect
WH FIB 100 8 1.8a
Twentyman & RIF I 100 7 No effect
Workman (1983)
Present Study SA FAC 100 -70 8 No effect
SA FAd 100 -70 8 No effect
aTumour response assessed by plating cells after excision. All other studies have used
growth delay to assay the response.
bEnhancement ratio=
MTD Melphalan alone(15mgkg to achieve the same growth Melphalan dose with MISO
delay.
CMelphalan given at the end of 8h chronic administration.
dMelphalan given halfway through the 8h chronic administration.
seen in every study: A threshold dose of 300-
500mgkg-1 seems to be needed. Only two studies
at doses of 500mgkg-1 or below have demon-
strated chemosensitization (Rose et al., 1980;
Sheldon et al., 1982) and two other studies have
shown no effect at 500mgkg-1 (Fu et al., 1981;
Twentyman & Workman, 1982). Far fewer studies
have been published using chronic MISO with
melphalan. In these, two different tumours have
been used, and in each case one study shows an
extra cytotoxicity with the combination whilst the
other shows none. With the RIF-1 tumour the same
assay was used in different laboratories, whereas
with WH FIB two different assays used by the
same workers led to opposite conclusions. These
studies were all performed with MISO levels of226 V.S. RANDHAWA el al.
l00 igml - in blood, which are similar to those
in the present study and also to those likely to be
achieved in the clinic. The evidence for an increased
effectiveness of melphalan combined with
prolonged low dose MISO is seen from Tables I
and II to be less than compelling.
As the MISO dose is increased above
200mgkg-1 the total exposure of tumour cells to
the drug would change, partly because of the higher
peak concentration and also due to the extension of
the half-life seen at high MISO doses (Workman,
1980). Several in vitro studies have indicated that
hypoxic cytotoxicity is more dependent upon
exposure time (T) than peak concentration (C)
(Hall et al., 1978; Stratford & Adams, 1978) and
has been correlated with a time squared expression
i.e. cytotoxicity ocC x T2 (Hall et al., 1978).
The present set of data allows us to analyse this
for the four schedules which have been compared.
In Figure 5 the additional delay resulting from
MISO treatment (relative to give 10mgkg-1
melphalan alone) has been plotted as a function of
the tumour exposure to MISO, calculated from
Cx T (panel A) or form C x T2 (panel B). The data
for chronic exposures fall below the data for acute
single doses in both panels but the discrepancy is
even greater for the C x T2 calculation than for the
simpler C x T If MISO cytotoxicity plays a role in
chemosensitization then these in vivo results do not
support the concept of cytotoxicity being a
supralinear function of overall time. Rather they
stipport the view that a critical threshold level is
needed, regardless of exposure time, to achieve
additional tumour cell kill.
Large MISO doses cause a drop in body and
tumour temperature which may influence many
physiological and biochemical parameters, including
respiration and heart rate, blood flow to tumour
and normal tissues and the rate of various
biochemical processes. The hydrolysis of melphalan,
and its interaction with DNA (alkylation), could
also be influenced by the changes in temperature.
Figure 4 and Table I demonstrate that changes in
the rate of melphalan removal from the plasma and
tumour occur with large single doses of MISO. The
extended plasma half-life has been reported by
Stephens et al. (1981), Clutterbuck (1982) and
Hinchliffe et al. (1983), but tumour measurements
have not previously been available. Since changes in
melphalan pharmacokinetics occur with high MISO
doses it is possible that the chemosensitization
observed with melphalan and MISO can be
explained by increased exposure of the tumour cells
to melphalan.
In Figure 5C, the additional delay from the
combined treatment has been plotted as a function
of tumour exposure to melphalan (calculated as
Cx T). For the 21°C data alone, it could be argued
that the changes in melphalan exposure to the
tumour could explain the observed effect. However,
when the mice are maintained at 35°C the extension
of the melphalan T112 and hence the exposure dose
are both reduced, yet the combined treatment is
more effective than any of the others, whereas the
effect of melphalan alone is unchanged (Figure 2B).
It is likely that several competing processes are
occurring and the overall balance between them
under different conditions will determine the
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Figure 5 MISO induced delay when combined with 10mgkg-1 melphalan plotted as a function of MISO or
melphalan exposure dose. (a) MISO dose =AUC; (b) MISO dose=concentration x time2: (c) melphalan
dose=AUC. (-) 500mgkg-1; (*) 1000mgkg-1, 21°C; (0) lOOOmgkg-1, 35°C; (7) chronic MISO, with
melphalan after 4h; (-) chronic MISO, with melphalan after 8 h.
:0
M
CU
'a
V
n0 @1
LI
~0
C/CHEMOSENSITIZATION OF MELPHALAN BY MISO 227
response observed. Enhanced alkylation and/or
reduced repair of sublethal lesions in the DNA may
both be involved.
The effects with cyclophosphamide were very
similar i.e. an increase in tumour growth delay after
large single doses of MISO. All the factors
mentioned above would apply to this result, but in
addition the rate at which the cyclophosphamide is
metabolised to its active form could also be
influenced by changes in body temperature.
Sieman (1984) recently reviewed the field of
electron affinic radiosensitizers when combined with
a variety of chemotherapeutic agents. He concluded
that no single unifying mechanisms for chemo-
sensitization exists and that changes in drug
pharmacokinetics, cellular SH levels and repair of
DNA damage are all involved. He also concluded
that, although a therapeutic gain has generally been
seen for large sensitizer doses, the results with
clinically achievable dose levels needed further
evaluation.
The present results indicate that low dose chronic
MISO administration is ineffective, in this
fibrosarcoma when combined with melphalan or
cyclophosphamide. The chemosensitization by large
single doses does not appear to be an artefact of
the hypothermia that accompanies it, but rather
seems to indicate that a critical peak MISO
concentration (>70igg-') must be achieved in the
tumour (Figure 3 and Table I). This could be
attained clinically with large infrequent MISO
doses, but the number of doses would be limited by
the cumulative toxicity. However, since chemo-
therapy is usually given as large infrequent doses
over many months, the toxicity experience from
repeated smallish dosing in radiotherapy studies 2-5
times a week over 6-8 weeks may be a pessimistic
guide to the tolerable MISO dose if it were
combined with chemotherapy.
We are grateful to Roche Products Ltd., Welwyn Garden
City, Herts, for misonidazole; Wellcome Foundation Ltd.,
Crewe, Cheshire, for melphalan; Boehringer Ingelheim
Ltd., Bracknell, Berks, for cyclophosphamide and the
Cancer Research Campaign for financing this work. We
should like to thank Mr P. Russell and the animal house
staff for care of the mice, Mrs J. Wilson and Mrs J.
Arnold for secretarial assistance and Prof. J.F. Fowler
and Dr S.A. Hill for constructively critical comments.
References
CLEMENT, J.J., GORMAN, M.S., WODINSKY, I., CATANE,
R. & JOHNSON, R.K. (1980). Enhancement of
antitumor activity of alkylating agents by the radiation
sensitizer misonidazole. Cancer Res., 40, 4165.
CLUTTERBUCK, R.D., MILLAR, J.L. & McELWAIN, T.J.
(1982). Misonidazole enhancement of the action of
BCNU and melphalan against human melanoma
xenografts. Am. J. Clin. Oncol., 5, 73.
DISCHE, S., SAUNDERS, M.I., FLOCKHART, R., LEE, M.E.
& ANDERSON, P. (1979). Misonidazole - a drug for
trial in radiotherapy and oncology. Int. J. Radiat.
Oncol. Biol. Phys., 5, 851.
FU, K., PHILLIPS, T.L., RAYNER, P.A. & ROSS, G.Y.
(1981). The combined effects of misonidazole and
chemotherapy on tumour and normal tissue in vivo.
Abstract. Proceedings of the 29th Annual Meeting of
the Rad. Res. Soc., p. 90.
HALL, E.J., MILLER, R., ASTOR, M. & RINI, F. (1978). The
nitroimidazoles as radiosensitizers and cytotoxic
agents. Br. J. Cancer, 37, (Suppl. III), 120.
HIRST, D.G. & BROWN, J.M. (1982). The therapeutic
potential of misonidazole enhancement of alkylating
agent cytotoxicity. Int. J. Radiat. Oncol. Biol. Phys., 8,
639.
HINCHLIFFE, M., MCNALLY, N.J. & STRATFORD, M.R.L.
(1983). The effect of radiosensitizers on the
pharmacokinetics of melphalan and cyclophosphamide
in the mouse. Br. J. Cancer, 48, 375.
MARTIN, W.M.C., McNALLY, N.J. & De RONDE, J. (1981).
Enhancement of the effect of cytotoxic drugs by
radiosensitizers. Br. J. Cancer, 43, 756.
MILLAR, B.C. (1982). Hypoxic cell radiosensitizers as
potential adjuvants to conventional chemotherapy for
the treatment of cancer. Biochem. Pharmacol., 31,
2439.
McNALLY, N.J., HINCHLIFFE, M. & De RONDE, J. (1983).
Enhancement of the action of alkylating agents by
single high, or chronic low doses of misonidazole. Br.
J. Cancer, 48, 271.
RANDHAWA, V.S., STEWART, F.A. & DENEKAMP, J.
(1982). Chemosensitization of mouse tumours by
misonidazole. Int. J. Radiat. Oncol. Biol. Phys., 8, 671.
ROSE, C.M., MILLAR, J.L., PEACOCK, J.H., PHELPS, T.A. &
STEPHENS, T.C. (1980). Differential enhancement of
melphalan cytotoxicity in tumor and normal tissue by
misonidazole. In: Radiation Sensitizers Their Use in the
Clinical Management of Cancer. (Ed. Brady), USA:
Masson Publ., p. 250.
SHELDON, P.W., BATTEN, E.L. & ADAMS, G.E. (1982).
Potentiation of melphalan activity against a murine
tumour by nitroimidazole compounds. Br. J. Cancer,
46, 525.
SIEMANN, D.W. (1982). Potentiation of chemotherapy by
hypoxic cell radiation sensitizers - A review. Int. J.
Radiat. Oncol. Biol. Phys., 8, 1029.
SIEMANN, D.W. (1984). Modification of chemotherapy by
nitroimidazoles. Int. J. Radiat. Oncol. Biol. Phys., 10,
(In press).
STRATFORD, I.J. & ADAMS, G.E. (1978). The toxicity of
the radiosensitizer misonidazole towards hypoxic cells
in vitro: A model for mouse and man. Br. J. Radiol.,
51, 745.
E228 V.S. RANDHAWA et al.
STEPHENS, T.C., COURTENAY, V.D., MILLS, J., PEACOCK,
J.H., ROSE, C.M. & SPOONER, D. (1981). Enhanced cell
killing in Lewis lung carcinoma and a human
pancreatic-carcinoma xenograft by the combination of
cytotoxic drugs and misonidazole. Br. J. Cancer, 43,
451.
TWENTYMAN, P. & WORKMAN, P. (1982). Effect of
misonidazole or metronidazole pretreatment on the
response of the RIF-1 mouse sarcoma to melphalan,
cyclophosphamide, chlorambucil and CCNU. Br. J.
Cancer, 45, 447.
TWENTYMAN, P.R. & WORKMAN, P. (1983). An
investigation of the possibility of chemosensitization
by clinically achievable concentrations of misonidazole.
Br. J. Cancer, 47, 187.
WORKMAN, P. (1980). Dose-dependence and related
studies on the pharmacokinetics of misonidazole and
desmethylmisonidazole in mice. Cancer Chemother.
Pharmacol., 5, 27.